Company intelligence / Profile preview

LifeTime Pharmaceuticals, Inc.

Lanham, Maryland, United Stateslifetimepharm.com.au ↗

Ownership: Private
Development stage: Commercial

Overview

The company conducted Phase 1/2 clinical trials for beta-alethine (also called Beta LT) in multiple myeloma, B-cell lymphoma, and Waldenstrom's macroglobulinemia. The trials aimed to assess the safety and efficacy of low doses of beta-alethine, which was designed to stimulate the immune system and stop cancer cells from growing[3].

Therapeutic areas: Oncology
Modalities: Biological therapies
Industry: Biotech

Drug pipeline

3 assets

coenzyme q10

Commercial

Indications: Dietary supplement

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on LifeTime Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LifeTime Pharmaceuticals, Inc..

Explore the full profile